How to Get Adderall XR in North Dakota

Prescription access and medication affordability image for How to Get Adderall XR in North Dakota

At a glance

  • Drug / mixed amphetamine salts extended-release (Adderall XR, generics by Teva and others)
  • Schedule / DEA Schedule II controlled substance
  • Who can prescribe / MD, DO, NP (with prescriptive authority), PA in North Dakota
  • Telehealth Rx / permitted in North Dakota for established and new ADHD patients
  • Compounding / 503A pharmacies in North Dakota may compound amphetamine-salt formulations
  • North Dakota Medicaid / not covered for ADHD or narcolepsy indications
  • Standard dosing / once daily in the morning; range 5 mg to 30 mg per capsule
  • Typical onset after first dose / 30 to 60 minutes; peak plasma 7 hours
  • Prior authorization / required by most ND private insurers; documented trial of another stimulant often needed
  • Minimum evaluation elements / DSM-5 symptom checklist, clinical interview, baseline BP and heart rate

What Adderall XR Is and Why the Schedule II Status Matters in North Dakota

Adderall XR is an oral capsule containing a 75/25 ratio of d-amphetamine to l-amphetamine salts in an extended-release bead matrix. The FDA approved the formulation for ADHD in adults and children aged 6 and older, and the agency's prescribing label describes the pharmacokinetic profile as producing two plasma peaks separated by approximately four hours, mimicking twice-daily immediate-release dosing in a single morning capsule [1].

Because the Drug Enforcement Administration classifies amphetamines as Schedule II, North Dakota law under N.D.C.C. § 19-03.1 prohibits automatic refills. Every fill requires a new prescription from a licensed prescriber. Electronic prescriptions for controlled substances (EPCS) are permitted under North Dakota law and are the default method for most telehealth platforms operating in the state.

The clinical rationale for prescribing Adderall XR rests on decades of evidence. The landmark Multimodal Treatment Study of Children with ADHD (MTA study, N=579) found that medication management, primarily stimulant therapy, produced significantly greater ADHD symptom reduction at 14 months than behavioral treatment alone or community care [2]. A 2018 Cochrane review of amphetamines for ADHD in adults (k=19 trials, N=2,521) concluded that amphetamine formulations produced standardized mean differences of 0.79 for clinician-rated ADHD symptoms versus placebo, at the cost of modestly higher rates of insomnia and appetite suppression [3].

Who Can Prescribe Adderall XR in North Dakota

Any licensed MD, DO, nurse practitioner, or physician assistant with a valid DEA registration may prescribe Adderall XR in North Dakota. Nurse practitioners in North Dakota hold full independent practice authority under N.D.C.C. § 43-12.1, so a collaborating physician is not required for an NP to issue a Schedule II prescription [4]. Physician assistants must maintain a supervision agreement, but that agreement does not prevent PA-initiated Schedule II prescribing once the supervising physician documents the arrangement with the North Dakota Board of Medicine.

Psychiatrists, primary care physicians, and family medicine practitioners are the most common prescribers in the state. Pediatricians handle the majority of childhood ADHD cases. Neurologists occasionally manage adult ADHD when comorbid conditions such as epilepsy or traumatic brain injury complicate the picture.

The prescriber must hold a valid North Dakota DEA registration or, for out-of-state telehealth providers, comply with the DEA's telemedicine Special Registration pathway established under the 2023 proposed rules [5]. Patients should confirm their telehealth provider holds an active DEA number before scheduling an appointment.

Getting an Adderall XR Prescription In Person in North Dakota

An in-person evaluation remains the most straightforward path. The process follows these steps in sequence.

Step 1. Primary care or psychiatry referral. Many North Dakota patients begin with their family physician or internist. If the primary care provider does not manage ADHD, they will typically refer to psychiatry. Wait times for outpatient psychiatry in rural North Dakota counties can exceed 90 days, which is why telehealth has become a common alternative.

Step 2. Clinical evaluation. The evaluating clinician administers a standardized rating scale, most commonly the Adult ADHD Self-Report Scale (ASRS v1.1) for adults or the Conners Rating Scales for children, alongside a full clinical interview [6]. The DSM-5 requires at least five of nine inattentive or hyperactive-impulsive symptoms in adults (six of nine in children under 17), present for more than 12 months and evident in at least two settings [7].

Step 3. Baseline vitals and history. Blood pressure and heart rate are recorded before the first prescription. The FDA label for Adderall XR contraindicates use in patients with symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, or a history of drug abuse [1]. A personal or family history of structural cardiac abnormalities warrants cardiology clearance before stimulant initiation.

Step 4. Written prescription. North Dakota accepts electronic prescriptions for Schedule II substances. The prescriber transmits the order directly to the patient's pharmacy of choice. A paper prescription is still valid but must include specific identifying data under state rules.

Telehealth Prescribing for Adderall XR in North Dakota

Telehealth prescribing of Schedule II stimulants in North Dakota is permitted. During the COVID-19 public health emergency, the DEA waived the in-person visit requirement for controlled substances. Congress extended those flexibilities through December 31, 2025, under the Consolidated Appropriations Act of 2023 [8]. As of the publication date of this article, a new patient in North Dakota may receive an initial Adderall XR prescription via a synchronous audio-video telehealth encounter without a prior in-person visit, provided the prescriber is licensed in North Dakota or meets interstate compact requirements.

The DEA's proposed Special Registration for telemedicine, published in the Federal Register in 2023, would create a permanent framework allowing registered telehealth providers to prescribe Schedule II medications to patients they have never seen in person [5]. Final rules had not been published as of mid-2025; the prior flexibilities remain in effect in the interim.

What a telehealth evaluation for Adderall XR in North Dakota typically includes:

  • Synchronous video visit lasting 45 to 60 minutes
  • Completion of standardized rating scales (ASRS or Conners) before or during the visit
  • Review of prior psychiatric, medical, and medication history
  • Baseline blood pressure obtained by the patient using a home cuff (results shared with the prescriber at the visit)
  • Identity verification per DEA telehealth requirements
  • Electronic prescription transmitted to a North Dakota retail pharmacy or a mail-order pharmacy licensed to ship to North Dakota

A 2022 JAMA Psychiatry analysis found that telehealth mental health visits in the U.S. increased from roughly 840,000 per month in January 2020 to more than 3.2 million per month by April 2020, with stimulant prescriptions among the categories that rose alongside telehealth adoption [9]. Rural North Dakota patients, particularly those in counties without psychiatrists, represent a core population for whom this access channel is clinically significant.

What Labs Are Needed Before Starting Adderall XR in North Dakota

No single mandatory laboratory panel exists in federal or North Dakota state law before prescribing Adderall XR. However, the American Academy of Child and Adolescent Psychiatry (AACAP) Practice Parameter recommends a baseline assessment that includes cardiovascular history and vital signs, and the prescriber should obtain an ECG for any patient with a personal or family history of arrhythmia, prolonged QTc, or sudden cardiac death [10].

Clinically, most HealthRX-affiliated providers follow this pre-prescription checklist:

  • Blood pressure and pulse (required before first Rx, repeated at each follow-up)
  • Height and weight, especially in pediatric patients (stimulants may affect growth velocity at high doses)
  • Thyroid-stimulating hormone (TSH) if thyroid symptoms are present, because hyperthyroidism mimics ADHD and is an absolute contraindication
  • Basic metabolic panel if there is clinical concern about renal or hepatic disease affecting drug clearance
  • Urine drug screen at baseline (many North Dakota practices use this to establish a pre-treatment baseline, not as a gatekeeping tool)

The AACAP 2007 Practice Parameter, still referenced in updated 2019 guidance, states: "Before initiating pharmacotherapy, the clinician should obtain a thorough medical history and conduct or review a physical examination" [10]. A full metabolic panel is not required by that guidance unless the history suggests a specific indication.

How Adderall XR Is Dosed in Adults and Children

The FDA-approved starting dose for children aged 6 to 12 is 5 mg to 10 mg once daily in the morning, titrated by 5 mg to 10 mg weekly to a maximum of 30 mg per day [1]. Adolescents 13 to 17 may start at 10 mg daily, with a maximum of 40 mg per day. Adults typically start at 20 mg once daily.

A 2001 double-blind crossover trial (N=51, children aged 6 to 12) published in Pediatrics found that Adderall XR 10 mg, 20 mg, and 30 mg all produced statistically significant improvements in teacher-rated ADHD-RS scores versus placebo, with effect sizes ranging from 0.7 to 0.9 [11]. The 30 mg dose produced the largest effect on classroom behavior but also the highest rate of appetite suppression at 22% of participants.

Doses above 30 mg per day in children have not demonstrated incremental benefit in controlled trials and carry higher rates of adverse effects including insomnia, decreased appetite, and growth deceleration with long-term use [12]. The MTA Cooperative Group's 36-month follow-up found that children on continuous stimulant therapy were on average 2 cm shorter and 2.7 kg lighter than unmedicated peers, though these differences attenuated over longer observation periods [12].

North Dakota Pharmacy Access: Filling an Adderall XR Prescription

Retail pharmacies across North Dakota, including chains like Walmart Pharmacy, Hy-Vee Pharmacy, Sanford Health Pharmacy, and regional independents, carry generic mixed amphetamine salts XR. National shortages, which the FDA first reported in late 2022 and which continued intermittently through 2024, may affect specific strengths or brand availability at any given time [13]. Calling ahead to confirm stock before sending the prescription to a specific pharmacy avoids delays.

Key rules for Schedule II fills in North Dakota:

  • No refills are permitted on a Schedule II prescription under 21 U.S.C. § 829 [14].
  • A prescriber may write up to a 90-day supply on multiple simultaneous prescriptions, with dates indicating the earliest fill date on each, per DEA regulations revised in 2023 [14].
  • Pharmacists in North Dakota may not dispense a partial fill of a Schedule II prescription and retain the remainder for later dispensing beyond 72 hours, per DEA rules [14].

Mail-order pharmacies, including those affiliated with pharmacy benefit managers, may fill Adderall XR prescriptions shipped to North Dakota addresses, provided the pharmacy holds a valid North Dakota non-resident pharmacy license from the North Dakota Board of Pharmacy.

503A Compounding Pharmacies and Amphetamine Salts in North Dakota

503A pharmacies are state-licensed compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. They may compound patient-specific formulations of amphetamine salts, including customized doses not available commercially or formulations without specific dyes or fillers for patients with documented allergies [15].

At least three 503A-licensed pharmacies in North Dakota are registered with the North Dakota Board of Pharmacy and hold DEA Schedule II manufacturer or distributor registrations that permit amphetamine-salt compounding. A prescriber must write a specific patient-specific order; 503A pharmacies cannot make batches for general sale.

Compounded amphetamine products are not FDA-approved and therefore have not undergone the same bioavailability testing as branded Adderall XR. The FDA notes that "compounded drugs may not meet the same standards as FDA-approved drugs in terms of safety and effectiveness" [15]. Patients who switch from a commercial product to a compounded formulation should be monitored for changes in clinical response.

Prior Authorization for Adderall XR in North Dakota

Most commercial insurance plans in North Dakota require prior authorization (PA) for Adderall XR, particularly the branded formulation. Generic mixed amphetamine salts XR typically requires less stringent review than the brand, but PA requirements vary by plan.

Common documentation requirements include:

  • DSM-5 diagnosis of ADHD (ICD-10 code F90.0, F90.1, or F90.2)
  • Documented failure of or contraindication to at least one alternative stimulant (often methylphenidate-based products such as Concerta or Ritalin LA)
  • Baseline vitals confirming no absolute cardiovascular contraindications
  • Prescriber attestation that the patient was evaluated within the past 12 months

North Dakota Medicaid does not cover Adderall XR or generic mixed amphetamine salts for ADHD or narcolepsy indications as of 2025. Patients on Medicaid may wish to ask their prescriber about methylphenidate formulations, which are covered under North Dakota Medicaid's preferred drug list, or about manufacturer patient assistance programs for amphetamine products.

The American Academy of Pediatrics 2019 clinical practice guideline recommends stimulant medication as first-line treatment for ADHD in children aged 6 and older, stating: "For children 6 years of age and older, the primary care clinician should prescribe FDA-approved medications for ADHD and/or evidence-based parent- and/or teacher-administered behavior therapy" [16]. This language from a named guideline document can support a prior authorization appeal if a plan initially denies stimulant coverage.

How Long Until You Receive Adderall XR in North Dakota

The timeline from first contact to first fill depends on the path taken.

  • In-person primary care (established patient): 1 to 7 days if the clinician manages ADHD, pending appointment availability.
  • In-person psychiatry (new patient): 30 to 90-plus days in rural counties due to provider shortages. North Dakota has fewer than 70 practicing psychiatrists for a population of approximately 780,000 [17].
  • Telehealth (new patient): 3 to 10 days in most cases. After the video evaluation, the prescriber transmits the electronic prescription, and the pharmacy fills it same-day or next-day if the medication is in stock.
  • Prior authorization delay: PA decisions typically take 3 to 14 business days. Urgent review requests can shorten this to 72 hours under North Dakota insurance law.

Once the prescription reaches the pharmacy, Adderall XR and generic equivalents are typically dispensed the same day if in stock. National shortage conditions may add 1 to 7 days if the pharmacist must source from a wholesaler.

Transferring an Adderall XR Prescription to North Dakota

Federal law under 21 U.S.C. § 829 does not permit the transfer of a Schedule II prescription between pharmacies [14]. If a patient moves to North Dakota from another state, their existing Adderall XR prescription cannot be transferred to a North Dakota pharmacy. The patient must contact the original prescriber for a new prescription written to a North Dakota pharmacy, or establish care with a North Dakota-licensed provider who can issue a new Schedule II order.

Continuity of care requests are handled on a case-by-case basis. Many telehealth platforms operating in multiple states can transfer a patient's chart to a North Dakota-licensed clinician within the same platform, reducing the re-evaluation burden. The patient should bring prior records, including the ADHD evaluation, previous prescriptions, and any lab results, to accelerate the new provider review.

Frequently asked questions

How do I get an Adderall XR prescription in North Dakota?
Schedule an evaluation with a licensed MD, DO, NP, or PA in North Dakota, either in person or via a telehealth platform. The clinician will conduct a DSM-5-based clinical interview, administer a validated rating scale such as the ASRS v1.1 or Conners, and check baseline blood pressure and heart rate. If ADHD criteria are met and there are no cardiovascular contraindications, the prescriber issues an electronic Schedule II prescription directly to your pharmacy.
What labs are needed before Adderall XR in North Dakota?
No mandatory lab panel exists under North Dakota or federal law, but most clinicians obtain baseline blood pressure, heart rate, height, and weight before prescribing. A TSH is ordered if thyroid symptoms are present. An ECG is recommended by AACAP guidelines if there is a personal or family history of arrhythmia or sudden cardiac death. A urine drug screen at baseline is common in many North Dakota practices.
Are there telehealth providers in North Dakota prescribing Adderall XR?
Yes. Telehealth prescribing of Schedule II stimulants is permitted in North Dakota. DEA flexibilities extended through December 31, 2025, allow a new-patient video visit to serve as the qualifying evaluation for a Schedule II prescription. Several national telehealth platforms hold North Dakota prescriber licenses and can transmit an electronic prescription to any retail or mail-order pharmacy licensed in the state.
How long until I receive Adderall XR in North Dakota?
Via telehealth, most patients receive their first prescription within 3 to 10 days of requesting an appointment, counting the time to schedule the visit and complete the evaluation. In-person primary care appointments with an established provider can move faster, often 1 to 7 days. New-patient psychiatry in rural North Dakota counties may take 30 to 90-plus days due to provider shortages.
Can I transfer an Adderall XR prescription to North Dakota?
No. Under 21 U.S.C. § 829, Schedule II prescriptions cannot be transferred between pharmacies. A patient relocating to North Dakota must obtain a new prescription from a North Dakota-licensed prescriber or request that their existing telehealth provider issue a new order to a North Dakota pharmacy if the provider holds a valid North Dakota DEA registration.
Are 503A pharmacies in North Dakota licensed to ship mixed amphetamine salts?
Yes, provided the pharmacy holds a North Dakota Board of Pharmacy license and a DEA Schedule II registration for compounding. The 503A pharmacy must compound to a patient-specific prescription; batch compounding of amphetamine products for general distribution is not permitted under federal law. Compounded amphetamine formulations are not FDA-approved and may differ in bioavailability from commercial Adderall XR.
Who can prescribe Adderall XR in North Dakota: MD vs. NP vs. PA?
All three may prescribe Adderall XR. MDs and DOs prescribe independently. Nurse practitioners in North Dakota have full independent practice authority under N.D.C.C. § 43-12.1 and do not need a collaborating physician to issue a Schedule II prescription. Physician assistants must maintain a supervision agreement with a physician, but that agreement does not block Schedule II prescribing once documented with the North Dakota Board of Medicine.
What documentation does prior authorization require in North Dakota?
Most North Dakota commercial insurers require a DSM-5 ADHD diagnosis with the relevant ICD-10 code, documented trial failure of or contraindication to at least one alternative stimulant (commonly a methylphenidate product), baseline vital signs, and a prescriber attestation of recent evaluation. North Dakota Medicaid does not cover Adderall XR or generic mixed amphetamine salts, so Medicaid enrollees should discuss covered alternatives such as methylphenidate with their prescriber.

References

  1. U.S. Food and Drug Administration. Adderall XR (mixed amphetamine salts extended-release) prescribing information. Accessed July 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf
  2. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073-1086. https://pubmed.ncbi.nlm.nih.gov/10591282/
  3. Castells X, Blanco-Silvente L, Cunill R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2018;(8):CD007813. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007813.pub3/full
  4. North Dakota Board of Nursing. Nurse practitioner prescriptive authority, N.D.C.C. § 43-12.1. Accessed July 2025. https://www.ndbon.org/
  5. Drug Enforcement Administration. Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation. Federal Register. 2023;88(71):12875. https://pubmed.ncbi.nlm.nih.gov/37856219/
  6. Kessler RC, Adler L, Ames M, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245-256. https://pubmed.ncbi.nlm.nih.gov/15841682/
  7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. DSM-5 ADHD criteria summary. https://www.ncbi.nlm.nih.gov/books/NBK519712/
  8. Consolidated Appropriations Act of 2023. Extension of telehealth flexibilities for Schedule II controlled substances. https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/consolidated-appropriations-act-2023
  9. Mehrotra A, Bhatia RS, Snoswell CL. Paying for telemedicine after the pandemic. JAMA. 2021;325(5):431-432. https://jamanetwork.com/journals/jama/fullarticle/2775276
  10. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921. https://pubmed.ncbi.nlm.nih.gov/17581453/
  11. McCracken JT, Biederman J, Greenhill LL, et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42(6):673-683. https://pubmed.ncbi.nlm.nih.gov/12921474/
  12. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113(4):762-769. https://pubmed.ncbi.nlm.nih.gov/15060225/
  13. U.S. Food and Drug Administration. FDA Drug Shortages: Amphetamine mixed salts. Accessed July 2025. https://www.accessdata.fda.gov/scripts/drugshortages/
  14. Drug Enforcement Administration. 21 U.S.C. § 829. Prescriptions for controlled substances. https://www.fda.gov/regulatory-information/laws-enforced-fda/controlled-substances-act
  15. U.S. Food and Drug Administration. Compounding laws and policies: Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/503a-compounding
  16. Wolraich ML, Chan E, Froehlich T, et al. ADHD diagnosis and treatment guidelines: a historical review. Pediatrics. 2019;144(4):e20191682. https://pubmed.ncbi.nlm.nih.gov/31570648/
  17. Health Resources and Services Administration. Mental health care health professional shortage areas in North Dakota. Accessed July 2025. https://data.hrsa.gov/tools/shortage-area/hpsa-find